These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 19322255)

  • 21. The concept of "tailor-made", protein-based, outer membrane vesicle vaccines against meningococcal disease.
    Holst J; Feiring B; Naess LM; Norheim G; Kristiansen P; Høiby EA; Bryn K; Oster P; Costantino P; Taha MK; Alonso JM; Caugant DA; Wedege E; Aaberge IS; Rappuoli R; Rosenqvist E
    Vaccine; 2005 Mar; 23(17-18):2202-5. PubMed ID: 15755595
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Control of epidemic group A meningococcal disease in Auckland.
    Lennon D; Gellin B; Hood D; Leach DT; Woods GM; Williams P; Thakur S; Crombie D
    N Z Med J; 1993 Jan; 106(948):3-6. PubMed ID: 8423925
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effectively introducing a new meningococcal A conjugate vaccine in Africa: the Burkina Faso experience.
    Djingarey MH; Barry R; Bonkoungou M; Tiendrebeogo S; Sebgo R; Kandolo D; Lingani C; Preziosi MP; Zuber PL; Perea W; Hugonnet S; Dellepiane de Rey Tolve N; Tevi-Benissan C; Clark TA; Mayer LW; Novak R; Messonier NE; Berlier M; Toboe D; Nshimirimana D; Mihigo R; Aguado T; Diomandé F; Kristiansen PA; Caugant DA; Laforce FM
    Vaccine; 2012 May; 30 Suppl 2():B40-5. PubMed ID: 22607898
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Properties and clinical performance of vaccines containing outer membrane vesicles from Neisseria meningitidis.
    Holst J; Martin D; Arnold R; Huergo CC; Oster P; O'Hallahan J; Rosenqvist E
    Vaccine; 2009 Jun; 27 Suppl 2():B3-12. PubMed ID: 19481313
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Reducing inequalities with vaccines: New Zealand's MeNZB vaccine initiative to control an epidemic.
    Lennon D; Reid S; Stewart J; Jackson C; Crengle S; Percival T
    J Paediatr Child Health; 2012 Mar; 48(3):193-201. PubMed ID: 21996021
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phase II meningococcal B vesicle vaccine trial in New Zealand infants.
    Jackson C; Lennon DR; Sotutu VT; Yan J; Stewart JM; Reid S; Crengle S; Oster P; Ypma E; Aaberge I; Mulholland K; Martin DR
    Arch Dis Child; 2009 Oct; 94(10):745-51. PubMed ID: 18838420
    [TBL] [Abstract][Full Text] [Related]  

  • 27. From tailor-made to ready-to-wear meningococcal B vaccines: longitudinal study of a clonal meningococcal B outbreak.
    Caron F; du Châtelet IP; Leroy JP; Ruckly C; Blanchard M; Bohic N; Massy N; Morer I; Floret D; Delbos V; Hong E; Révillion M; Berthelot G; Lemée L; Deghmane AE; Bénichou J; Lévy-Bruhl D; Taha MK
    Lancet Infect Dis; 2011 Jun; 11(6):455-63. PubMed ID: 21489881
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Surveillance of vaccine breakthrough cases following MeNZB vaccination.
    McNicholas A; Galloway Y; Martin D; Sexton K; O'Hallahan J
    N Z Med J; 2008 Apr; 121(1272):38-46. PubMed ID: 18425153
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Proceedings of the Meningococcal Vaccine Strategy World Health Organization satellite meeting, 10 March 2004, Auckland, New Zealand.
    Sexton K; Lennon D; Oster P; Aaberge I; Martin D; Reid S; Wong S; O'Hallahan J
    N Z Med J; 2004 Aug; 117(1200):1 p preceding U1027. PubMed ID: 15481128
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prevention of group B meningococcal disease by vaccination: a difficult task.
    Thomas M
    N Z Med J; 2004 Aug; 117(1200):U1016. PubMed ID: 15475986
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Serogroup A meningococcal conjugate vaccine coverage after the first national mass immunization campaign-Burkina Faso, 2011.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2012 Dec; 61(50):1022-4. PubMed ID: 23254256
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Successful intervention in a group A meningococcal outbreak in Auckland, New Zealand.
    Lennon D; Gellin B; Hood D; Voss L; Heffernan H; Thakur S
    Pediatr Infect Dis J; 1992 Aug; 11(8):617-23. PubMed ID: 1523071
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Safety and immunogenicity of New Zealand strain meningococcal serogroup B OMV vaccine in healthy adults: beginning of epidemic control.
    Thornton V; Lennon D; Rasanathan K; O'Hallahan J; Oster P; Stewart J; Tilman S; Aaberge I; Feiring B; Nokleby H; Rosenqvist E; White K; Reid S; Mulholland K; Wakefield MJ; Martin D
    Vaccine; 2006 Feb; 24(9):1395-400. PubMed ID: 16242221
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Optimizing protection against meningococcal disease.
    Reisinger KS; Black S; Stoddard JJ
    Clin Pediatr (Phila); 2010 Jun; 49(6):586-97. PubMed ID: 20089551
    [TBL] [Abstract][Full Text] [Related]  

  • 35. New Zealand's epidemic of meningococcal disease described using molecular analysis: implications for vaccine delivery.
    Dyet K; Devoy A; McDowell R; Martin D
    Vaccine; 2005 Mar; 23(17-18):2228-30. PubMed ID: 15755601
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Evolution of meningococcal disease in the community of Madrid. Effectiveness of antimeningococcal A+C vaccination].
    Gutiérrez Rodríguez MA; Ramírez Fernández R; García Gutiérrez J; Moreno Civantos A; Hernando García M; Arce Arnáez A; Sendra Gutiérrez JM; Bueno Vallejos R
    Rev Esp Salud Publica; 2000; 74(4):397-403. PubMed ID: 11031849
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The role of MeNZB vaccination in controlling the New Zealand meningococcal epidemic.
    Lennon D
    N Z Med J; 2008 Mar; 121(1270):110-2. PubMed ID: 18364765
    [No Abstract]   [Full Text] [Related]  

  • 38. The risk of simple febrile seizures after immunisation with a new group B meningococcal vaccine, New Zealand.
    Stehr-Green P; Radke S; Kieft C; Galloway Y; McNicholas A; Reid S
    Vaccine; 2008 Feb; 26(6):739-42. PubMed ID: 18187240
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The legacy of MeNZB and possible implications for COVID-19 vaccination.
    Reid JS
    N Z Med J; 2020 Nov; 133(1525):114-118. PubMed ID: 33223554
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mum's the word: factors that influenced young adults' participation in the New Zealand Meningococcal B immunisation programme.
    Bland M; Clear GM; Grogan A; Hoare K; Waldock J
    N Z Med J; 2009 Dec; 122(1307):30-8. PubMed ID: 20148042
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.